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Obesity associated alterations in the biology of
adipose stem cells mediate enhanced
tumorigenesis by estrogen dependent pathways
Amy L Strong1, Thomas A Strong1, Lyndsay V Rhodes2, Julie A Semon1, Xiujuan Zhang1, Zhenzhen Shi1,
Shijia Zhang1,4, Jeffrey M Gimble1,3, Matthew E Burow2 and Bruce A Bunnell1,4*

Abstract
Introduction: Obesity has been associated with increased incidence and mortality of breast cancer. While the
precise correlation between obesity and breast cancer remains to be determined, recent studies suggest that
adipose tissue and adipose stem cells (ASCs) influence breast cancer tumorigenesis and tumor progression.
Methods: Breast cancer cells lines were co-cultured with ASCs (n = 24), categorized based on tissue site of origin
and body mass index (BMI), and assessed for enhanced proliferation, alterations in gene expression profile with PCR
arrays, and enhanced tumorigenesis in immunocompromised mice. The gene expression profile of ASCs was assess
with PCR arrays and qRT-PCR and confirmed with Western blot analysis. Inhibitory studies were conducted by
delivering estrogen antagonist ICI182,780, leptin neutralizing antibody, or aromatase inhibitor letrozole and assessing
breast cancer cell proliferation. To assess the role of leptin in human breast cancers, Oncomine and Kaplan Meier
plot analyses were conducted.
Results: ASCs derived from the abdominal subcutaneous adipose tissue of obese subjects (BMI > 30) enhanced
breast cancer cell proliferation in vitro and tumorigenicity in vivo. These findings were correlated with changes in
the gene expression profile of breast cancer cells after co-culturing with ASCs, particularly in estrogen receptoralpha (ESR1) and progesterone receptor (PGR) expression. Analysis of the gene expression profile of the four
groups of ASCs revealed obesity induced alterations in several key genes, including leptin (LEP). Blocking estrogen
signaling with ICI182,780, leptin neutralizing antibody, or letrozole diminished the impact of ASCs derived from
obese subjects. Women diagnosed with estrogen receptor/progesterone receptor positive (ER+/PR+) breast cancers
that also expressed high levels of leptin had poorer prognosis than women with low leptin expression.
Conclusion: ASCs isolated from the abdomen of obese subjects demonstrated increased expression of leptin,
through estrogen stimulation, which increased breast cancer cell proliferation. The results from this study
demonstrate that abdominal obesity induces significant changes in the biological properties of ASCs and that
these alterations enhance ER+/PR+ breast cancer tumorigenesis through estrogen dependent pathways.

Introduction
Breast cancer is the most frequently diagnosed cancer in
women and the second leading cause of cancer deaths in
the United States. While many risk factors increase the
incidence of breast cancer, obesity is among one of the
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most important risk factors for breast cancer in postmenopausal women as it not only increases the incidence of breast cancer but also the mortality rate due to
poor prognosis and outcome [1-4]. Obesity has been
shown to affect prognosis through multiple mechanisms,
including enhanced metastasis rate and drug resistance
[5,6]. Furthermore, recent studies have demonstrated a
stronger correlation between abdominal obesity and breast
cancer [7,8].
While the precise link between obesity and breast cancer remains to be determined, previous studies have
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described the activation of adipose stem cells (ASCs) in
the presence of breast cancer to contribute to its pathogenesis [9,10]. ASCs are mesenchymal lineage stem cells
that are recruited to the tumor or sites of inflammation
and are essential components that establish the tumor
microenvironment [11-13]. This recruitment enhances
tumor growth through the secretion of an abundance of
growth factors from ASCs, such as IL-6, CCL5 and
PDGR, which have been shown to contribute to both
the breast cancer tumorigenesis and the metastasis of
breast cancer cells [14,15].
While previous studies have determined that ASCs
play an integral role in the progression of breast tumors,
the impact of obesity and abdominal obesity on the relationship between cancer and ASCs has not been investigated. Studies have revealed that ASCs isolated from
subjects with vastly different body mass indices display
differences in their secretory profile, angiogenic potential
and invasive capacity [16,17]. Recent work by Kolonin et
al. demonstrated increased numbers of ASC in obese
mice relative to lean mice, and this increase in ASC
number enhances vascularization and proliferation of
malignant cells [13]. The results from these studies suggest that the local microenvironment from which these
ASCs are isolated can influence their gene expression
profiles. In addition, the site of origin of the adipose tissue from which the ASCs are derived may alter essential
cellular signaling pathways that may directly influence
breast cancer tumorigenesis.
This study investigated the impact of ASCs, isolated
from different subcutaneous adipose depots in subjects
with increasing body mass index (BMI), on the
growth, gene expression profile and tumorigenesis of
breast cancer cells. The results from this study demonstrated that ASCs isolated from abdominal depots
of obese subjects (BMI >30) enhanced breast cancer cell
growth and tumorigenesis via an estrogen mediated
response.

Methods
Human subjects

All protocols were reviewed and approved by the Pennington
Biomedical Research Center Institutional Review Board
and all human participants provided written informed
consent (PBRC #23040). Human ASCs were obtained
from 24 Caucasian females (4 groups, 6 donors per group)
undergoing elective liposuction procedures, as previously
described [18,19]. Briefly, ASCs were isolated from processed lipoaspirates from subcutaneous abdominal adipose
tissue of obese (Ob+Ab+) or non-obese (Ob-Ab+) subjects
and from non-abdominal subcutaneous adipose depots of
obese (Ob+Ab-) and non-obese (Ob-Ab-) subjects. Liposuction aspirates were incubated in 0.1% type I collagenase
(Sigma) and 1% powered bovine serum albumin (BSA,
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fraction V; Sigma, St. Louis, MO, USA) dissolved in
100 ml of phosphate buffered saline (PBS) supplemented
with 2 mM calcium chloride. This mixture was placed in a
37°C shaking water bath at 75 rpm for 60 minutes and
then centrifuged to remove oil, fat, primary adipocytes and
collagenase solution, leaving behind a pellet of cells. Cells
were resuspended in complete culture media (CCM), which
consisted of α-Minimal Essential Medium (αMEM; GIBCO;
Grand Island, NY, USA), 20% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA, USA), 100 units per ml
penicillin/100 μg/mL streptomycin (P/S; GIBCO), and
2 mM L-glutamine (GIBCO), and plated on 150 cm2 culture dishes. Fresh CCM was added every two to three
days until cells achieved 80 to 90% confluence, at which
time cells were harvested with 0.25% trypsin/1 mM
EDTA (GIBCO) and cryopreserved prior to experimental use. Non-abdominal subcutaneous adipose tissue
was isolated from the hip, knee, thigh, ankle, flank,
upper toroso, scapula, forearm, arm and back. The
mean BMI for each of the four donor groups was as follows: Ob+Ab+ (32.7 ± 3.7), Ob+Ab- (31.1 ± 0.6), Ob-Ab+
(22.7 ± 1.9) and Ob-Ab- (22.5 ± 1.2). The mean age of the
subjects for each group of donors was as follows: Ob+Ab+
(42.5 ± 8.9), Ob+Ab- (44.0 ± 12.4), Ob-Ab+ (38.8 ± 7.0) and
Ob-Ab- (52.4 ± 18.0). No statistical significance in age was
observed between the donor groups.
Cell culture
ASCs

Frozen vials of ASCs were thawed and cultured on
150 cm2 culture dishes (Nunc, Rochester, NY, USA) in
25 ml CCM and incubated at 37°C with 5% humidified
CO2. After 24 hours, viable cells were harvested with
0.25% trypsin/1 mM EDTA and replated at 100 cells/cm2
in CCM. Media was changed every two to three days. For
all experiments, sub-confluent cells (≤70% confluent) between passages 2 to 6 were used.
To characterize the cells, ASCs were induced to undergo
osteogenic and adipogenic differentiation. For osteogenic
differentiation, ASCs were cultured in six-well plates in
CCM until 70% confluent and media was replaced with
fresh media containing osteogenic supplements, consisting of 50 μM ascorbate 2-phosphate (Sigma), 10 mM βglycerol phosphate (Sigma) and 10 nM dexamethasone.
After three weeks, cells were fixed in 10% formalin for
1 hour at 4°C and stained for 10 minutes with 40 mM
Alizarin Red (pH 4.1) to visualize calcium deposition in
the extracellular matrix. Images were acquired at 4×
magnification on Nikon Eclipse TE200 (Melville, NY,
USA) with Nikon Digital Camera DXM1200F using the
Nikon ACT-1 software version 2.7. For adiogenic differentiation, ASCs were cultured in six-well plates in CCM
until 70% confluent, and media was replaced with fresh
media containing adipogenic supplements, consisting
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of 0.5 μM dexamethasone (Sigma), 0.5 mM isobuytlmethylxanthine (Sigma) and 50 μM indomethacin
(Sigma). After three weeks, cells were fixed in 10% formalin for 1 hour at 4°C, stained for 10 to 15 minutes at
room temperature with Oil Red O (Sigma) to detect
neutral lipid vacuoles, and images were acquired at 10×
magnification on Nikon Eclipse TE200 with Nikon
Digital Camera DXM1200F using Nikon ACT-1 software version 2.7.
To determine the ability to form colony forming units
(CFU), ASCs at passage 3 were plated at a density of 100
cells on a 10 cm2 plate in CCM and incubated for 14 days.
Plates were rinsed three times with PBS, and 10 mL of 3%
crystal violet (Sigma) was added for 30 minutes at room
temperature. Plates were washed three times with PBS
and once with tap water. Each experiment was performed
in triplicate.
Analysis by flow cytometry of the cell surface marker
profile was conducted by harvesting ASCs with 0.25%
trypsin/1 mM EDTA for three to four minutes at 37°C.
A total of 3×105 cells were concentrated by centrifugation at 500 x g for five minutes, suspended in 50 μl PBS
and labeled with the primary antibodies. The following
primary antibodies were used: Anti-CD45-PeCy7, antiCD11b-PeCy5, anti-CD166-PE, anti-CD105-PE, anti-CD90PeCy5, anti-CD34-PE, isotype-control FITC human IgG1
and isotype-control PE human IgG2a were purchased
from Beckman Coulter (Indianapolis, IN, USA). AntiCD44-APC was purchased from BD Biosciences (San Jose,
CA, USA). The samples were incubated for 30 minutes at
room temperature and washed three times with PBS. The
samples were then analyzed with Galios Flow Cytometer
(Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). To assay cells by forward and
side scatter of light, FACScan was standardized with
microbeads (Dynosphere Uniform Microspheres; Bangs
Laboratories Inc.; Thermo Scientific, Waltham, MA, USA).
At least 10,000 events were analyzed and compared with
isotype controls.
Breast cancer cell lines

MCF7 and MDA-MB-231 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM; GIBCO), supplemented with 10% FBS and P/S.
Cells were grown at 37°C with 5% humidified CO2, fed
every two to three days, and split 1:4 to 1:6 when they
reached 90% confluency.
Synthesis of GFP breast cancer cells

To produce retroviruses carrying green fluorescent protein (GFP) and neomycin resistance (neo), 293T cells
were transfected by means of a modified calcium chloride transfection protocol when cells reached 90 to 95%
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confluency. The following amount of DNA was used to
transfect cells on a 10 cm plate: 10 μg pMSCVneo-GFP
vector, 10 μg pVPACK-Gp-dl packaging plasmid, and
10 μg pCI-VSV-G envelope-encoding plasmid. Twentyfour hours after transfection, cells were washed with
PBS, replaced with fresh media, and collected after
48 hours. To transduce MCF7 or MDA-MB-231 cells,
conditioned media containing retrovirus was added
to MCF7 or MDA-MB-231 cells at 70% confluency.
MCF7 cells were selected with 1 mg/ml of Genticin
(Invitrogen, Carlsbad, CA, USA), while MDA-MB-231
cells were selected with 500 μg/ml of Genticin for two week
and GFP expression was verified with flow cytometry.
Breast cancer cell and ASC co-culture

MCF7 cells or MDA-MB-231 cells were co-cultured
with Ob-Ab- (n = 6), Ob-Ab+ (n = 6), Ob+Ab-(n = 6), or
Ob+Ab+ (n = 6) ASCs (1:1 ratio) at 200 cells/cm2 in
DMEM supplemented with 10% FBS and P/S. After
seven days, cells were harvested, washed and analyzed
by flow cytometry. The percentage of GFP positive cells
(MCF7 cells or MDA-MB-231) was determined with
Gallios Flow Cytometer running Kaluza software
(Beckman Coulter, Brea, CA, USA) (Figure 1A). Where
indicated, MCF7 cells were co-cultured with Ob-Ab-,
Ob-Ab+, Ob+Ab-, or Ob+Ab+ ASCs (1:1 ratio) grown in
CCM made with charcoal dextran stripped-FBS (CDSFBS) with or without supplemental estrogen (E2; 10
nM), leptin neutralizing antibody (R&D Systems;
Minneapolis, MN, USA), or letrozole (Sigma). For RNA
isolation, MCF7 cells were sorted after co-culture with
the Becton-Dickinson FACSVantage SE Cell Sorter with
DiVa option (BD Biosciences, Franklin Lakes, NJ, USA)
and analyzed with the DiVa software v5.02 (BD).
ASC conditioned media

ASCs, pooled from six donors per group, were plated on at
150 cm2 culture dish at 100 cells/cm2. After overnight culture, media was replaced with serum free αMEM medium.
After seven days, conditioned media was collected and filtered to remove debris. ASC conditioned media from each
group was plated on top of MCF7 cells set up in triplicates.
After seven days, the total number of MCF7 cells were
counted with a hemocytometer. Three independent experiments were conducted, each in triplicate.
RT2 profiler™ PCR arrays
Breast cancer PCR arrays

Total cellular RNA was extracted from FACS purified
MCF7 cells after co-culture with a pool of ASCs (n = 6
per group) or MCF7 control cells (not co-cultured)
using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and
treated with DNase I digestion (Qiagen) according to
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Figure 1 Direct co-culture of breast cancer cells with ASCs result in increased proliferation in vitro. (A) After seven days of co-culture (CC)
with six adipose stem cells (ASC) donors per group, quantification of MCF7 cells and MDA-MB-231 (231) cells was based on the percentage of
GFP+ cells in the population multiplied by the total number of cells in each condition. (B) To determine the influence of ASCs on MCF7 cells
indirectly, conditioned media (CM) from pooled ASCs (n = 6 donors per group) were collected and added to MCF7 cells. After seven days, the
total number of MCF7 cells was counted. Values reported are the mean of three independent experiments, each performed in triplicate.
Bars, ± SD. *, P <0.05; #, P <0.01.

manufacturer’s instructions. One μg of RNA was
converted to cDNA with the RT2 First Strand Kit
(SABiosciences, Frederick, MD, USA) according to the
manufacturer’s protocol. Gene expression profiling was
performed using the Breast Cancer RT2 Profiler PCR
Array (SABiosciences) and RT2 qPCR Master Mix
(SABiosciences). PCR amplification was performed in a
Bio-Rad CFX96 Real-Time System (Bio-Rad, Hercules,
CA, USA). The reaction conditions were as follows:
95°C for 10 minutes, 40 cycles of 95°C for 15 sec and
60°C for 1 minute, followed by a dissociation curve.
At the completion of the reaction, Ct values were
determined, and ΔΔ Ct and fold change were determined using the RT2 Profiler PCR Array Data Analysis
web portal (SABiosciences). Genes whose mRNA
levels increased or decreased more than two-fold in
MCF7 cells after co-culture with ASCs relative to
MCF7 cells without co-culture were considered differentially expressed (P <0.05).
Obesity PCR arrays

Ob-Ab- (n = 6), Ob-Ab+ (n = 6), Ob+Ab- (n = 6) or Ob+Ab+
(n = 6) ASCs were expanded in CCM and collected for
RNA extraction using the RNeasy Mini Kit, and the total
cellular RNA was treated with DNase I per the manufacturer’s instructions. One μg of RNA was converted to
cDNA with the RT2 First Strand Kit according to the
manufacturer’s protocol. Gene expression profiling was
performed using the Obesity RT2 Profiler PCR Array
(SABiosciences) and RT2 qPCR Master Mix. Reaction settings and analysis was conducted as described above.

Genes whose mRNA levels increased or decreased more
than two-fold (P <0.05) in MCF7 cells after co-culture
with ASCs relative to MCF7 cells without co-culture were
considered differentially expressed.

Western blot

MCF7 cells and FACS sorted MCF7 cells after cocultured with ASC donors (n = 6 per group) were incubated in phosphatase and protease inhibitors (Pierce,
Thermo Scientific, Rockford, IL, USA), lysed with RIPA
buffer (Pierce), and centrifuged. Cell lysate was also
obtained from Ob-Ab- (n = 6), Ob-Ab+ (n = 6), Ob+Ab(n = 6), or Ob+Ab+ (n = 6) ASCs cultured in CCM made
with charcoal dextrose stripped FBS (Atlanta Biologicals, Lawrenceville, GA, USA). Where indicated, ASCs
were treated with 10 nM 17β-estradiol (E2, Sigma, St.
Louis, MO, USA) and/or 100 nM ICI182,780 (Sigma),
and cell lysate was obtained. A total of 20 μg of protein
was fractionated on 4 to 12% SDS-polyacrylamide gels
(Invitrogen) and transferred to nitrocellulose membranes (Invitrogen). The blots were blocked with blØk
Noise Canceling Reagents (Millipore, Billerica, MA,
USA) and probed using primary antibodies incubated
overnight at 4°C, washed with phosphate-buffered solution with 0.01% TWEEN-20 (PBST), followed by a secondary antibody conjugated to horseradish peroxidase
(HRP), washed with PBST and visualized with chemiluminescence reagent (Invitrogen) on an ImageQuant
LAS 4000 (GE Healthcare Life Science; Piscataway,
NJ, USA).
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Antibodies against cyclin dependent kinase inhibitor 2A
(CDKN2A), estrogen receptor-alpha (ESR1), and progesterone receptor (PGR) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-secreted
frizzled-related protein 1 (anti-SFRP1), anti-mouse-HRP,
anti-rabbit-HRP antibodies were purchased from Abcam
(Cambrige, MA). Anti-glutathione S-transferase P (antiGSTP1) was purchased from Cell Signaling Technologies
(Danvers, MA, USA), anti-actin was purchased from
Sigma, and anti-leptin was purchased from R&D Systems.
In vivo tumorigenicity assay

All procedures involving animals were conducted in
compliance with State and Federal law, standards of the
US Department of Health and Human Services, and
guidelines established by Tulane University Institutional
Animal Care and Use Committee (IACUC). All protocols were approved by the Tulane IACUC.
SCID/beige (CB17.Cg-PrkdcscidLystbg-J/Crl) immunocompromised female ovariectomized mice (five weeks
old) were obtained from Charles River Laboratories
(Wilmington, MA, USA). Mice were divided into
treatment groups of five animals, with or without estrogen: MCF7 only, MCF7 plus Ob-Ab- ASCs (n = 6
donors), MCF7 plus Ob-Ab+ ASCs (n = 6 donors),
MCF7 plus Ob+Ab- ASCs (n = 6 donors), and MCF7
plus Ob+Ab+ ASCs (n = 6 donors). Where indicated,
estradiol pellets (0.72 mg, 60-day release, Innovative Research of America, Sarasota, FL, USA) were implanted
subcutaneously in the lateral area of the neck.
MCF7 cells (106) alone or MCF7 cells (106) in combination with ASCs (106) suspended in a total volume of 50 μl
of sterile PBS were mixed with 100 μl of reduced growth
factor Matrigel (BD Biosciences, Bedford, MA, USA). Cells
were injected subcutaneously into the fifth mammary fat
pad on both sides. All procedures in animals were carried
out under anesthesia using a mixture of isoflurane and
oxygen delivered by mask.
Tumor size was measured every three days using
digital calipers and calculated as previously described
[20]. At necropsy, animals were euthanized by cervical
dislocation after exposure to CO2. Tumors were removed and frozen in liquid nitrogen or fixed in 10%
neutral buffered formalin and paraffin embedded for further analysis.
Immunohistochemistry

Formalin-fixed, paraffin-embedded (FFPE) tumor sections were deparaffinized, rehydrated in a graded solution of Sub-X solutions, stained with hematoxylin and
eosin or quenched with 0.3% H2O2 (Sigma), rinsed with
PBST, blocked with 1% BSA and stained with primary
antibodies against Ki-67 (Abcam) or human progesterone
receptor (PGR; DAKO North America, Inc., Carpinteria,
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CA, USA) overnight at 4°C. Each tumor section was subsequently washed in PBST, incubated with appropriate
HRP-conjugated secondary antibody for one hour at room
temperature, and washed with PBST. For colorimetric
staining, slides were then incubated in 3,3'-Diaminobenzidine (DAB; Vector Laboratories; Burlingame, CA, USA),
washed with PBST, counterstained with hematoxylin, and
rinsed with deionized water. Slides were sealed with Permount Mounting Medium (Sigma). For apoptosis analysis,
the TACS-XL in situ Apopotosis Detection Kit (R&D Systems) was used according to the manufacturer’s instructions. After staining, tumor sections were counterstained
and sealed as mentioned above. Images were acquired at
10× and 40×. Quantification of the percentage of positivity
was assessed using ImageScope (Aperio, Vista, CA, USA)
and determined by the percentage of positive pixels divided by the total number of pixels in a given section.
Quantitative Reverse Transcription-Polymerase Chain
Reaction (qRT-PCR)

Ob-Ab- (n = 6 donors), Ob-Ab+ (n = 6 donors), Ob+Ab(n = 6 donors), or Ob+Ab+ (n = 6 donors) ASCs cultured
in CCM were collected for total cellular RNA extraction
using a RNeasy Mini Kit. Where indicated, ASCs were
cultured in CCM containing charcoal dextrose-stripped
FBS, with or without supplementation with 10 nM E2
and/or 100 nM ICI182,780. RNA was then purified with
DNase I digestion (Invitrogen), and reverse transcribed
using the SuperScript VILO cDNA synthesis kit (Invitrogen). Quantitative real-time PCR was performed using
the EXPRESS SYBR GreenER qPCR SuperMix Kit (Invitrogen) according to the manufacturer’s instructions.
The following primer set sequence for leptin (forward
5′-gaagaccacatccacacacg-3′, reverse 5′-agctcagccagacccatcta-3′) and aromatase (forward 5′-cagaggccaagagtttgagg-3′, reverse 5′-acactagcaggtccctttgg-3′) were used.
β-actin (forward 5′-caccttctacaatgagctgc-3′ and reverse
3′-tcttctcgatgctcgacgga-5′) was used as an internal reference point. At the completion of the reaction, ΔΔCt was
calculated to quantify mRNA expression.
Oncomine analysis

A set of 440 normal breast tissues and invasive ductal
carcinomas (IDC) deposited by The Cancer Genome
Atlas (TCGA) was analyzed using the Oncomine Research Edition to assess leptin expression. Details of the
standardized normalization techniques and statistical
calculations can be found on the Oncomine website
(http://www.oncomine.com).
KM plot analysis

To determine the five-year relapse-free survival of patients diagnosed with breast cancer based on leptin expression, an online survival analysis tool was utilized
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and can be found on the Kaplan-Meier Plotter website
(http://www.kmplot.com). Details of the standardized
normalization techniques and characterization of high
or low expression have been previously described [21].
Statistical analysis

All values are presented as means ± standard deviation
(SD). The statistical differences among two or more
groups were determined by ANOVA, followed by post-hoc
Dunnet multiple comparison tests versus the respective
control group. The statistical differences between two
groups were performed by Student’s t-test. Statistical significant was set at P <0.05. Analysis was performed using
Prism (Graphpad Software, San Diego, CA, USA).

Results
Characterization of ASCs

ASCs were isolated from lipoaspirates of obese (Ob+) and
non-obese (Ob-) subjects undergoing elective plastic surgery and from the subcutaneous abdominal adipose tissue
(Ab+) or non-abdominal subcutaneous depots (Ab-). Each
ASC donor (n = 24), irrespective of the ASC group the
donor was categorized into, was analyzed for the expression of cell surface markers and were positive for CD44,
CD90, CD105 and CD166 and negative for CD34, CD45
and CD11b determined with flow cytometry (Additional
file 1). Each group of ASCs was able to generate colonyforming units and undergo osteogenesis and adipogenesis
(Additional file 1). No differences were observed among
the four groups for ASC differentiation or self-renewal
capacity as defined by colony forming units.
ASCs isolated from obese subjects enhance the
proliferation of MCF7 cells in vitro

To investigate the effect of the donor’s BMI status and
depot site on ASC interaction with breast cancer cells,
MCF7 cells or MDA-MB-231 cells were directly cocultured with ASCs from non-abdominal sources of nonobese subjects (Ob-Ab-), abdominal source of non-obese
subjects (Ob-Ab+), non-abdominal sources of obese subjects (Ob+Ab-), or abdominal sources of obese subjects
(Ob+Ab+). Irrespective of the depot site of origin or BMI,
ASCs increased the proliferation of MDA-MB-231 cells
(P <0.01), with no statistically significant difference
between the ASC groups (Figure 1A). However, ASCs
isolated from obese subjects increased the proliferation of
MCF7 cells: 1.5-fold (from 1.1×106 to 1.6×106 MCF7 cells)
after co-culture with Ob+Ab- ASCs (P <0.05) and 2.0-fold
(from 1.1×106 cells to 2.2×106 cells) after co-culture with
Ob+Ab+ cells (P <0.01; Figure 1A). MCF7 cells cocultured with ASCs isolated from non-obese subjects
failed to increase the cell number.
To determine whether ASCs can influence MCF7 cell
growth indirectly, conditioned media was collected from
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all four ASC groups and added to MCF7 cells. The total
number of MCF7 cells was assessed after seven days.
MCF7 cells grown in ASC conditioned media from
obese subjects increased their proliferation by 1.6-fold
(from 0.8×106 to 1.3×106 MCF7 cells after co-culture
with Ob+Ab- ASCs) and 1.9-fold (from 0.8×106 cells to
1.5×106 cells after co-culture with Ob+Ab+ cells), respectively (P <0.01; Figure 1A); while no statistically significant increase was observed when MCF7 cells were
exposed to ASC CM from non-obese donors.

Donors’ obesity status and depot site of the ASCs
influence their effect on the gene expression profile of
MCF7 cells

To determine whether the ASCs could induce changes
in the gene expression of MCF7 cells, a breast cancer
PCR array containing 84 genes known to contribute to
breast cancer tumorigenesis and progression was utilized.
Of the 84 genes assessed, 13 genes were significantly altered in MCF7 cells by direct co-culture with ASCs, irrespective of the categorical ASC group (P <0.05; Table 1).
Alterations in the expression of apoptotic, angiogenic,
signal transduction, glucocorticoid, metastasis, and xenobiotic transportation genes were observed. These genes included: BAD, SERPINE1, IL6, CDH13, SNAI2, BIRC5,
PGR, ESR1, IGFBP3, NME1, MMP2, MMP9 and ABCG2
(Table 1). However, the Ob+Ab+ ASCs altered the expression of an additional 14 unique genes in MCF7 cells
(P <0.05; Table 1). Alterations in the expression of cell
cycle, apoptotic, angiogenesis, metastasis, and adhesion
genes were observed. These genes included: CDKN2A,
CCND2, PTEN, SFRP1, PLAU, SLIT2, TWIST1, PTGS2,
THBS1, CSF1 and ADAM23. The complete comparative
analysis of changes in MCF7 gene expression profile after
co-culture with ASCs can be found in Additional file 2.

Increased expression of CDKN2A, GSTP1, SFRP1, ESR1 and
PGR in MCF7 cells after co-culture with ASCs

Western blot analysis was performed to confirm the altered gene expression related to cell cycle control, apoptosis and steroid receptors identified in the MCF7 cells on
the PCR array with fold changes greater than five-fold.
Cell cycle regulator CDKN2A, apoptotic gene GSTP1 and
SFRP1, and the steroid receptors ESR1 and PGR were analyzed. Robust increases in the levels of protein expression
for CDKN2A, GSTP1, SFRP1, ESR1 and PGR were observed
in MCF7 cells after co-culture with ASCs, irrespective of
the ASC group (P <0.05; Figure 2). However, co-culture
with Ob+Ab+ ASCs induced the most significant fold increase in the expression of CDKN2A (from 0.4 to 0.9),
GSTP1 (from 0.3 to 0.9), SFRP1 (from 0.1 to 0.3), ESR1
(from 1.1 to 1.7) and PGR (from 1.4 to 3.2) (P <0.05).
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Table 1 mRNA expression of MCF7 cells after exposure to ASCs
Functional gene
grouping

Gene

Cell cycle

MCF7 cells gene expression after CC with
Ob-Ab-

Ob-Ab+

Ob+Ab-

Ob+Ab+

CDKN2A

1.41

1.20

2.40

50.33*

CCND2

1.41

1.27

2.40

1.77*

PTEN

1.05

1.04

−1.07

−1.18*

GSTP1

9.79

22.15

17.99

2,475.21*,#

BAD

2.21*

2.01*

1.85*

1.33*

SFRP1

1.40

1.23

2.45

56.75#

SERPINE1

15.72*

33.81*

27.27*

4,672.57*,#

IL6

3.47*

5.44*

7.01*

197.63*,#

CDH13

3.65*

4.02*

4.64*

24.70*,#

PLAU

1.99

2.12

3.40

47.07#

SLIT2

3.15

2.42

1.05

30.48#

Hedgehog

SNAI2

4.47*

11.26*

7.41*

1,592.05*,#

Notch

BIRC5

3.17*

3.36*

3.42*

1.84*,#

Steroid receptor-mediated

PGR

4.15*

5.84*

12.72*

75.41*,#

Steroid receptor-mediated

ESR1

3.97*

4.68*

16.87*

26.85*,#

IGFBP3

15.47*

32.51*

15.03*

2,746.41*,#

NME1

2.86*

3.03*

3.12*

2.02*

MMP2

12.22*

24.35*

11.05*

2,320.15*,#

MMP9

3.52*

3.59*

4.46*

1.77*,#

TWIST1

1.45

1.31

2.51

278.20#

PTGS2

1.34

1.15

2.30

81.38#

THBS1

1.05

1.31

1.16

54.82*

CSF1

1.99

2.12

1.01

42.71*

ADAM23

1.42

1.33

1.27

Apoptosis

Angiogenesis

Signal transduction

Glucocorticoid

Metastasis

Adhesion

Xenobiotic transport

ABCG2

12.56*

12.09*

7.50*
,#

29.09*

12.70*

Up-regulated (+) or down-regulated (−) gene expression is shown as fold change relative to MCF7 cells without previous co-culture with ASCs. Values are normalized to
MCF7 cells without exposure to ASCs.
*P <0.05; #P <0.01.

Estrogen enhances the ASC-induced MCF7 cell proliferation
in vitro

Due to the marked increase in ESR1 and PGR expression in MCF7 cells, the effect of estrogen on the ASCinduced MCF7 cell proliferation was assessed. In the absence of estrogen, MCF7 cells demonstrated no significant change in cell proliferation after co-culture with
ASCs grown in CCM made with CDS-FBS (P >0.05;
Figure 3A), indicating that the depletion of estrogen and
other growth factors commonly found in FBS eliminated
the stimuli that enhanced cellular proliferation. The
addition of estrogen increased MCF7 proliferation 1.4-fold
(from 2.3×105 cells to 3.1×105 MCF7 cells) after seven
days. Estrogen induced proliferation was greatly increased
when MCF7 cells were co-cultured with ASCs isolated
from obese subjects, increasing the proliferation of MCF7

1.7-fold after co-culture with Ob+Ab- ASCs (from 3.1×105
cells to 5.3×105 MCF7 cells) and 1.9-fold after co-culture
with Ob+Ab+ ASCs (from 3.1×105 cells to 6.0×105
MCF7 cells) (P <0.05; Figure 3B). While co-culturing
MCF7 cells with ASCs isolated from non-obese subjects
increased the proliferation of the MCF7 cells, these results
were not statistically significant (Figure 3B).
Tumor volume of MCF7 and ASC xenografts is related to
the obesity status and depot source of the ASCs

To assess the role of ASCs in tumorigenesis, MCF7 cells
and ASCs were mixed and injected into the mammary
fat pad of ovariectomized immunocompromised SCID/
beige mice, and tumor volumes were measured regularly
over 36 days. In the absence of estrogen, MCF7 xenografts were 140 ± 9.8 mm3, while co-mixed xenografts
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Figure 2 Changes in the expression of cell cycle regulators
and steroid receptors of MCF7 cells. MCF7 cells were grown
alone or in the presence of ASCs (n = 6 donors per group) grouped by
the donor’s obesity status and depot site of ASCs for seven days. Cell
lysate from sorted GFP+ MCF7 cells was collected for Western blot
analysis of CDKN2A, GSTP1, SFRP1, ESR1 and PGR. Blots were then
stripped and probed for actin as a control.

(MCF7 and ASCs) were between 84.0 and 107.5 mm3,
with no statistically significant difference observed between
the four groups of co-mixed xenografts (Additional file 3).
These results suggest that in the absence of estrogen, ASCs
do not exert any influence on breast cancer tumorigenesis.
In the presence of estrogen, xenografts formed with
MCF7 cells became both easily palpable and visible by
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Day 36 compared to xenografts in the absence of estrogen (P <0.05; Figure 4A). The co-mixed xenografts
(MCF7 and ASCs) were significantly larger than the
MCF7 only xenografts (P <0.01; Figure 4A), suggesting
that estrogen may be mediating its effects by activating
the ASCs. Tumor volumes of xenografts formed with
ASCs isolated from non-obese subjects were similar in
size, irrespective of depot site of origin Ob-Ab+ ASCs
(TV = 816.5 ± 36.7 mm3) or Ob-Ab- ASCs (tumor volume
(TV) = 774.4 ± 38.2 mm3) (Figure 4A). However, xenografts formed with MCF7 cells and Ob+Ab+ ASCs
(TV = 1,779.6 ± 49.0 mm3) were significantly larger in
size than xenografts formed with Ob+Ab- ASC (TV =
1,230.0 ± 33.5 mm3) (P <0.05; Figure 4A). In the presence
of estrogen, irrespective of MCF7 cell or co-mixed xenografts, increased cellularity was observed, without distinction between the groups (Figure 4B).
In order to assess proliferation and apoptosis, tumor
sections were stained with Ki-67 and TUNEL. In the
presence of estrogen, co-mixed tumors consisting of
ASCs isolated from obese subjects, Ob+Ab- ASCs and
Ob+Ab+ ASCs, demonstrated higher proliferation rates
than MCF7-only xenografts. However, the co-mixed
tumors formed with MCF7 cells and Ob+Ab+ ASCs
demonstrated significantly more expression of Ki-67
(51.5% Ki-67 positive; P <0.05; Figure 4B, C). The detection of apoptotic cells demonstrated a lower frequency of apoptosis events in co-mixed tumors
formed with MCF7 and Ob+Ab+ ASCs with 6.5%
positive compared to 17.4% positive in MCF7 xenografts (P <0.05; Figure 4B, C).

Figure 3 Estrogen enhances the effect of ASCs on MCF7 proliferation in vitro. Adipose stem cells (ASCs) (n = 6 donors per group) were
co-cultured (CC) with MCF7 cells in media supplemented with charcoal dextran stripped fetal bovine serum. (A) After seven days, quantification
of MCF7 cells was based on the percentage GFP+ cells in the population multiplied by the total number of cells in the condition. (B) ASCs were
grown in 10 nM estrogen (E2) replenished every three days, and after seven days, quantification of MCF7 cells was based on the percentage of
GFP+ cells in the population multiplied by the total number of cells in each condition. Values reported are the mean of three independent experiments,
each performed in triplicate. Bars, ± SD. *, P <0.05.
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Figure 4 Donor’s obesity status and depot site of ASCs differentiates its influence on tumorigenicity in vivo. MCF7 cells alone (106) or
MCF7 cells and adipose stem cells (ASCs) (n = 6 donors per group) were co-mixed in a 1:1 ratio (106 of each cell type) in a total volume of 50 μl
of sterile PBS and mixed with 100 μl of reduced growth factor Matrigel™. Cells were injected into the fifth mammary fat pad of six-week old
female ovariectomized SCID/beige mice (n = 5 mice per group). Estrogen was delivered subcutaneously in the neck as a 0.72 mg 60-day
time-release estrogen pellet. Tumor volume was measured every 3 days for a total of 36 days. (A) Tumor volume of tumors formed with MCF7
cells alone or co-mixed cells (MCF7 and ASCs) injected into the mammary fat pad with or without estrogen pellet (E2). (B) Representative images
of H&E, Ki-67, TUNEL and PGR staining of tumor sections from tumor sections taken at 10x and 40x. Scale bars both represent 50 μm. (C) Quantification
of Ki-67, TUNEL and PGR staining with ImageScope represented as the percentage of positive pixels over total number of pixels per tumor section.
Values reported are means of 10 tumor sections. Bars, ± SD. *, P <0.05 between MCF7 and other groups. #, P <0.01 between MCF7 with estrogen and
other groups, **, P <0.001 between MCF7 and other groups.
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Enhanced progesterone receptor expression in xenografts
formed with Ob+Ab+ ASCs

Due to the increased tumor volume and decreased levels
of apoptosis observed in co-mixed xenografts formed
with MCF7 cells and Ob+Ab+ ASCs in the presence of
estrogen, the possibility of estrogen receptor (ER)-mediated signaling was further explored. Tumor sections
were stained for progesterone receptor (PGR), as PGR
expression is mediated by ER signaling and its increased
expression correlates with ER activation. The xenografts
formed in the absence of estrogen demonstrated no
PGR staining (Figure 4B; Additional file 3). In the presence of estrogen, PGR expression increased in all xenografts and was highest in the MCF7 cell/Ob+Ab+ ASCs
xenografts (20.9% PGR positivity) compared to 11.7% PGR
positivity in MCF7 only xenografts (P <0.05; Figure 4B, C).
Gene expression profiles differ between ASCs based on
obesity status and depot source

In order to explore quantifiable differences in gene expression between the groups of ASCs, a PCR array with
genes known to play a role in obesity was utilized. The
results demonstrated that the mRNA expression levels
of eight genes were altered between the Ob-Ab+ ASCs,
Ob+Ab- ASCs and Ob+Ab+ ASCs when compared to
Ob-Ab- ASCs: leptin (LEP), leptin receptor (LEPR), sortilin 1 (SORT1), thyrotropin-releasing hormone (TRH),
melanin-concentrating hormone 1 (MCHR1), peroxisome
proliferator-activated receptor-gamma (PPAR-gamma),
peroxisome proliferator-activated receptor gamma coactivator 1-α (PPARGC1A) and thyroid hormone receptor-β
(THRB) (P <0.05; Additional file 4; Additional file 5). Furthermore, the Ob+Ab+ ASCs demonstrated more robust
changes in the expression of both LEP (201.5-fold increase) and TRH (50.44-fold decrease; P <0.01; Additional
file 4; Additional file 5). The full comparative analysis of
the gene expression profile of the four groups of ASCs
can be found in Additional files 4 and 5.
Estrogen stimulates leptin expression in ASCs which then
enhances MCF7 proliferation

With the increased expression of leptin in Ob+Ab+ ASCs,
the potential ER-mediated response through leptin was
explored by exposing ASCs cultured in CDS-FBS to estrogen and/or ICI182,780, a steroidal estrogen antagonist.
The removal of endogenous estrogen in the FBS resulted
in no statistical alterations of leptin expression between
the groups (Figure 5A), with a 3.1-fold increase in Ob-AbASCs, 4.4-fold increase in Ob-Ab+ ASCs, 3.5-fold increase
in Ob+Ab- ASCs and 5.8-fold increase in Ob+Ab+ ASCs.
However, in the presence of estrogen, the expression of
leptin in the ASCs increased from 11.1- (Ob-Ab- ASCs),
37.2- (Ob-Ab+ ASCs), 18.7- (Ob+Ab- ASCs), and 128.8fold (Ob+Ab+ ASCs) (P <0.05; Figure 5A). While all of the

Page 10 of 15

groups of ASCs demonstrated an increase in leptin expression, the Ob+Ab+ ASCs demonstrated the greatest
fold increase (10-fold) in leptin expression compared to
the other groups (P <0.005; Figure 5A). These results suggest robust activation of Ob+Ab+ ASCs by estrogen. The
treatment of the cells with ICI182,780 in the presence estrogen reduced leptin expression in each group to pretreatment levels.
To confirm that the levels of leptin protein increased
in the ASCs, cells were cultured in CDS-FBS with or without supplementation of estrogen and probed for leptin expression by Western blot. Leptin levels in each ASC group
increased in the presence of estrogen (Figure 5B). In order
to prove that these results were not donor dependent,
each individual ASC donor was treated with estrogen and
probed for leptin expression. While some donor variability
was observed between the donors within a group, leptin
always increased and the levels of variability were not statistically significant. Moreover, all Ob+Ab+ ASC donors
demonstrated the greatest increase in leptin expression
compared to the other ASC donors (P <0.01; Figure 5C).
To determine the role of leptin in proliferation of breast
cancer cells, MCF7 cells were co-cultured with ASCs in
the presence of a neutralizing antibody to leptin. After
seven days, in the presence of the neutralizing antibody
and estrogen, MCF7 cells did not increase in proliferation,
irrespective of the ASC group (Figure 5D). These results
indicate that ASCs induce MCF7 proliferation, at least in
part, through an estrogen-mediated activation of leptin in
ASCs.
Enhanced ASC aromatase expression and activity
increases MCF7 cells

In order to assess local estrogen synthesis, ASCs were
grown in CCM and aromatase mRNA expression was
assessed. ASCs isolated from obese donors demonstrated
enhanced aromatase expression, as Ob-Ab-, Ob-Ab+, Ob+Aband Ob+Ab+ ASCs demonstrated 11.6-, 13.7-, 19.7- and
25.4-fold increase relative to MCF7 cells, respectively
(P <0.05; Figure 5E). Furthermore, ASCs isolated from
obese donors demonstrated greater aromatase expression
compared to non-obese donors (P <0.01). Furthermore,
delivery of aromatase inhibitors reduced the enhanced
proliferation of MCF7 cells due to the co-culture with
ASCs. MCF7 cells co-cultured with ASCs from obese subjects demonstrated the most significant reduction, with
the most significant decrease in Ob+Ab- ASCs (−66.3%)
and Ob+Ab+ ASCs (−131.4%) (P <0.01; Figure 5F).
High leptin levels correlate with poor relapse-free survival
in ER+/PR+ breast cancer

In order to assess expression of leptin in human breast
cancer samples, leptin expression was analyzed using the
TCGA cDNA microarray data set of breast cancers
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Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Estrogen exposure influences leptin expression in ASCs. (A) Adipose stem cells ASCs (n = 6 donors per group) were cultured in
media supplemented with charcoal dextran stripped FBS (CDS-FBS) supplemented with (E2) or ICI182,780. Cells were collected at 70% confluency
and total RNA was isolated for real-time PCR analysis of leptin expression. (B) Cell lysate was collected from n = 6 ASC donors cultured in CDS-FBS
with or without E2 at 70% confluency and subjected to Western blot analysis with 20 μg of protein and separated by SDS-page under reducing
conditions, blotted and probed with antibodies to leptin or actin. (C) Cell lysate was collected from six different ASCs donors and either pooled
or analyzed as individual donors (D#), cultured in CDS-FBS with or without estrogen. A total of 20 μg of protein was separated by SDS-page under
reducing conditions, blotted, and probed with leptin and actin antibodies. (D) ASCs (n = 6 donors per group) were co-cultured with MCF7 cells
and treated with vehicle (dimethyl sulfoxide, DMSO) neutralizing leptin antibody (Lep nAb), estrogen (E2) or neutralizing leptin antibody and
estrogen (Lep nAb + E2) in complete culture media (CCM) containing CDS-FBS. After seven days, the number of MCF7 cells was calculated based
on the percentage of GFP+ MCF7 cells by the total number of cells in the population. (E) ASCs (n = 6 donors per group) were cultured in CCM
and collected at 70% confluency and total RNA was isolated for real-time PCR analysis of aromatase expression. (F) ASCs (n = 6 donors per group)
were co-cultured with MCF7 cells and treated with letrozole (10 nM) in CCM. After seven days, the number of MCF7 cells was determined by the
percentage of GFP+ cells multipled by the total number of cells. Percent change was determined by the relative change in the number of MCF7
cells after letrozole treatment compared to their non-treated controls. Values reported are the mean of three independent experiments, each
performed in triplicate. Bars, ± SD. *, P <0.05; **, P <0.01; #, P <0.005.

deposited in Oncomine. Compared to normal breast tissue (n = 73), invasive ductal breast carcinoma (IBC; n =
367) demonstrated a 2.0-fold increase in expression (P =
0.005). To determine whether leptin expression related to
prognosis and the hormone status of the breast cancer,
further analysis was conducted with the Kaplan-Meier
(KM) Plotter. KM plots demonstrated that women diagnosed with ER+/PR+ breast cancers whose tumor also
expressed high levels of leptin (n = 25) demonstrated
poorer prognosis with increased mortality rates as compared to ER+/PR+ breast cancers with lower levels of leptin
(n = 73; P = 0.038; Figure 6A). In contrast, analysis of
leptin expression in women diagnosed with ER-/PRbreast cancer did not demonstrate a correlation between leptin and relapse-free survival outcomes (P =
0.15; Figure 6B). Together, this suggests that invasive
breast carcinoma overexpresses leptin compared to
normal breast tissue and that leptin levels may also
be a potential prognostic factor for ER+/PR+ invasive
breast carcinomas.

Discussion
The results of this study demonstrate that site of origin
and BMI alter the biologic properties of subcutaneous
human ASCs and their role in cancer tumorigenesis.
ASCs were categorized based on depot source and obesity status of the donor subject. ASCs isolated from obese
subjects led to the greatest increase in the proliferation
and tumorigenicity of MCF7 cells in vitro and in vivo via
an estrogen-activated response mediated through leptin.
Previous studies have explored the endocrine role of adipocytes on breast cancer cell proliferation and metastasis
[22]; however, only a few studies have examined the effects
of ASCs on breast cancer cell lines. Muehleberg et al.
demonstrated that ASCs increased the proliferation of a
murine breast cancer cell line and enhanced the invasion
and metastasis of cancer cells [14]. Utilizing ASCs isolated
from the breast and from abdominal adipose tissue,
Walter et al. demonstrated that the secretion of IL-6
from ASCs enhanced the migration and invasion of breast
cancer cells [10]. The results from this study provide further

Figure 6 Levels of leptin expression correlate with decreased survival in ER+/PR+ breast cancers. Kaplan Meier analysis of the probability
of five-year relapse-free survival of women diagnosed with (A) ER+/PR+ or (B) ER-/PR- breast cancers based on leptin expression.
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support for the role of ASCs in the tumor microenvironment. The data from this study demonstrated that ASCs effectively alter the gene expression profile of breast cancer
cells. More specifically, ASCs isolated from obese subjects
enhanced breast cancer cell proliferation and tumor volume
and ASCs isolated from the abdomen of obese subjects
(BMI >30) further altered the expression of several additional genes. These data provide additional support for the
role of obesity, especially abdominal obesity, in affecting
breast cancer prognosis. At present, the mechanism(s) by
which abdominal obesity induces changes in the ASCs is
not known. Rehrer et al. demonstrated differences in the
subcutaneous adipose tissue isolated from the hip and flank
compared to adipose tissue isolated from the abdomen, providing support for differences in adipose tissue based on
depot site [23]. More specifically, genes involved in the biochemical metabolism were expressed at higher levels in the
abdomen compared to the hip [23]. Additional studies into
the microenvironment of the adipose tissue in obese
subjects, prior to isolation, would provide substantial
insight into the influence of obesity on ASC biology.
Analysis of the gene expression profiles of the four
ASC groups revealed significant differences in leptin expression and further determined that the enhanced leptin levels were the direct result of exposure to estrogen.
The analysis of the four groups of ASCs, categorized
based on depot site and obesity status of the subject,
provides support for the potential of ASCs to alter breast
cancer cells. More specifically, while leptin expression
was increased in ASCs isolated from the abdomen of
non-obese subjects and from non-abdominal sources of
obese subjects, a more robust increase in leptin expression was observed in ASCs isolated from the abdomen
of obese subjects when the cells are exposed to estrogen.
Leptin has been shown to play a vital role in the progression of breast cancer through the activation of several signaling cascades. Delivery of leptin to breast
cancer cells enhances the proliferation rate through
the activation of the STAT3 and ERK1/2 signaling pathway and diminishes apoptosis through a significant reduction in p53 expression and Bax production [24,25].
Several studies suggest that leptin also exhibits estrogenproducing activity by enhancing aromatase expression and
enhances the sensitivity of breast cancer cells to estrogen
through the up-regulation of estrogen receptor alpha
[26,27]. In addition, the inhibition of leptin-signaling
results in diminished tumor growth and progression.
Animal studies demonstrate that subcutaneous injection
of leptin receptor antagonist peptide delayed the development and slowed the growth of breast cancer tumors, suggesting the involvement of leptin in tumor latency and
growth [28].
While ASCs isolated from the abdomen of obese subjects demonstrated an increase in leptin expression, the
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cells failed to elicit an effect on breast cancer cell proliferation or tumor growth. After exposure to estrogen the
ASCs increased in leptin expression and breast cancer
cell proliferation and tumor growth, suggesting that a
threshold of expression must be achieved before leptin
can effectively activate breast cancer cell proliferation.
These findings indicate that one of the primary mechanism(s) by which ASCs influence breast cancer is via
estrogen-mediated pathways. While this study did not
focus on the origins of the estrogen, it has been shown
that the adipose tissue of obese subjects produce significantly more estrogen through enhanced aromatase activity [29]. As such, enhanced estrogen production in the
adipose tissue of obese subjects could potentially stimulate an altered ASC phenotype to secrete an abundance
of leptin to alter the gene expression profile of breast
cancer cells.
The analysis of the gene expression profiles of breast
cancer cells after co-culture with ASCs indicate that the
ASCs can activate signaling cascades that enhance proliferation, reduce apoptosis, stimulate angiogenesis and
increase metastatic rate of breast cancer cells [10]. The
direct co-culture studies revealed the up-regulation of
CDKN2A, a cell cycle regulator, and GSTP1, a gene responsible for the detoxification of drugs, which have
been shown to be up-regulated in multi-drug resistant
breast cancer [30]. More specifically, Kars et al. demonstrated enhanced GSTP1 expression and CDKN2A expression among their pacilitaxel and vincristine resistant
MCF7 cell lines [30]. These results may suggest that
co-culturing ASCs isolated from the abdomen of obese
subjects may induce a multi-drug resistant MCF7 phenotype, but additional studies are necessary.
Although the studies described here utilized MCF7
and MDA-MB-231 cell lines, further analysis with additional ER+ breast cancer cell lines may provide insight
into the full capacity of ASCs to impact different types
of breast cancer. Further studies to evaluate the role of
additional adipokines in the conditioned media as well
as potential contribution of cell-cell interactions are necessary to fully understand the mechanism by which
ASCs influence breast cancer tumorigenesis and progression. Nevertheless, our study provides insight into
the variability among donors and within donors. While
previous studies have demonstrated significant variation
in the growth properties, osteogenic capacity and adipogenic capacity of bone marrow-derived stem cells and
adipose stem cells, respectively, the cause of the variability
between donors and between different aspirates within the
same donor have not been previously identified [31,32].
Herein, our study provides insights into the potential for
the depot site of origin as well as donor’s obesity status
to contribute to donor-to-donor variability and variability
observed within the same donor.
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The link between high leptin expression and prognosis
for breast cancer patients was determined to be significant in ER+/PR+ breast cancer. The analysis of leptin expression in primary breast cancer samples demonstrated
significant differences in normal breast tissue compared
to invasive ductal carcinoma [33,34]. It should be noted
that these publically available resources do not separate
the tumor stroma from the cancer cells, and as such increased leptin expression could correlate with increased
expression of leptin in the tumor stroma, where the
ASCs are localized. More detailed analysis of primary
breast cancer samples is needed to assess the cell type
expressing the leptin. However, the assessment of the
ASCs from obese and non-obese subjects as well as their
depot site suggest that more profound differences could
be observed, if obesity status could be taken into account. Since the patient population analyzed in these
two resources did not differentiate patients based on
obesity status, it would be expected that the results presented here would reveal only a limited scope on the effects of leptin on survival rate. Taken together, the
assessment of the effect of ASCs on breast cancer suggests that the tumor microenvironment consisting of
these ASCs could dictate the outcomes in obese patients.
Moreover, these findings suggest that leptin may be a
novel therapeutic target for breast cancer treatment in
obese patients.

Conclusion
This study demonstrates that ASCs are conditioned by
their local microenvironment in obese subjects as both
the donor’s obesity status and the site of deposition contribute to the stimulatory effects of ASCs on breast cancer
cell growth. Furthermore, the positive effects of estrogen
on leptin expression in ASCs suggest a potential mechanism by which these ASCs are elicited to influence breast
cancer cell proliferation and suggest a new avenue to be
explored for breast cancer treatment in obese patients.
Additional files
Additional file 1: Characterization of ASCs isolated from donors
based on obesity status and deposit site. (A) ASCs (n = 24) in each
of the four groups were stained with antibodies against the indicated
antigens and analyzed by flow cytometry. Represented cell surface
marker profiles for each group are shown. Histograms are shown as
colored lines and the respective isotype controls are in gray. (B) CFUs
were seeded at low density and incubated in CCM for 14 days. Cells
were fixed and stained with crystal violet. Images were captured with
a digital camera. Representative images for each group are shown.
(C) ASCs were grown until 70% confluent in CCM and then switched
to differentiation media. After 21 days, cells were fixed and stained with
Alizarin Red for osteogenesis and Oil Red O for adipogenesis.
Representative images for each group are shown. Original magnification
for osteogenesis is 4× and for adipogenesis is 10× for all panels. Scale
bars represent 100 μm.
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Additional file 2: Cluster diagram of relative gene expression of
MCF7 cells co-cultured with ASCs characterized by obesity status
and depot site of origin. Expression is relative to MCF7 cells without
exposure to ASCs.
Additional file 3: Tumorigenesis of MCF7 cells when co-mixed with
the 4 categorical ASC groups in the absence of estrogen. (A) Tumor
volume of MCF7 cells alone or co-mixed cells injected into the mammary
fat pad in the absence of estrogen. (B) Representative images of immunohistochemistry staining for human Ki-67, TUNEL, and PGR staining in
tumor sections. (C) Quantification of Ki-67, TUNEL and PGR staining with
ImageScope represented as the percentage of positive pixels over total
number of pixels per tumor section. All images were acquired at 10× and
40×. Scale bar represents 50 μm. Bars, ± SD. *, P <0.05.
Additional file 4: Cluster diagram of relative gene expression of
ASCs characterized by obesity status and depot site of origin.
Expression is relative to Ob-Ab- ASCs.
Additional file 5: Fold change in mRNA expression of ASCs based
on obesity status and depot site of origin. Values are normalized to
Ob-Ab- ASCs. *, P <0.05; #, P <0.01.
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SORT1: Sortilin1; TCGA: The Cancer Genome Atlas; THBS1: Thrombospondin
1; THRB: Thyroid hormone receptor-beta; TRH: Thyrotropin-releasing
hormone; TWIST1: Twist basic helix-loop-helix transcription factor 1.
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